Inca Minerals and South32 ready to attack Riqueza

|

Published 01-MAY-2019 15:37 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Having ratified its joint venture and earn in agreement with South32 Ltd (ASX:S32), Inca Minerals Ltd (ASX:ICG) provided an update on its activities at the Riqueza project in Peru, as well as underlining its intentions to embark on another joint-venture opportunity with a particular focus on low-cost opportunities that show early potential for large scale mineral systems.

At the time of the update Inca Minerals also advised that it had entered into binding arrangements to raise $289,500 (before raising costs), an initiative that will provide additional funds for upcoming exploration.

However, Riqueza remains the main game and having maintained a state of readiness at the site, the resumption of exploration operations focused on zinc and copper mineralisation is imminent.

Furthermore, a number of initiatives have been undertaken leading up to the exploration program that will assist the company in defining targets.

Exploration results to be available in coming months

Among other activities, WorldView3 satellite imagery has been ordered to further define targets.

The interpretation is being completed by the same firm that completed the headline geophysics target modelling.

Parallel to remote sensing work, planning for the two programs that includes detailed mapping, focusing on porphyry, skarn and structure and grid (geochemical) sampling are well advanced.

Expert porphyry-skarn-structure geologists will join management on site in early May.

The grid sampling program will generate over 1,800 samples and will provide geochemical heat map targets to overlay the geophysics targets.

The combination of geochemical and geophysical anomalies will further refine the potential targets for future drilling.

A comprehensive exploration program has been scheduled for the first year and the company expects a steady news flow of various exploration results in the coming months, a possible source of market moving developments.

Another potential share price catalyst is the securing of a new project as we discussed earlier.

The following demonstrates management’s methodology in selecting such a project.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X